首页>Japanese Journal of Clinical Oncology>Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma
作者单位：Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan[1]Department of Neurology, Hematology, Metabolism Endocrinology and Diabetology (DNHMED), Yamagata[2]
换一批
换一批
